Merck & Co Inc BDR (MRCK34)

56.09
-0.45(-0.80%)
  • Volume:
    14
  • Bid/Ask:
    55.95/56.09
  • Day's Range:
    56.07 - 56.54
  • Type:Equity
  • Market:Brazil
  • ISIN:BRMRCKBDR003

MRCK34 Overview

Prev. Close
56.54
Day's Range
56.07-56.54
Revenue
-
Open
56.54
52 wk Range
28.73-64
EPS
-
Volume
14
Market Cap
1.14T
Dividend (Yield)
1.3239
(2.51%)
Average Vol. (3m)
18,221
P/E Ratio
-
Beta
-
1-Year Change
69.54%
Shares Outstanding
2,525,943,936
Next Earnings Date
-
What is your sentiment on Merck & Co Inc BDR?
or
Vote to see community's results!

Merck & Co Inc BDR Company Profile

Employees
73500
Market
Brazil

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellSellNeutralStrong Buy
SummaryStrong SellStrong SellSellNeutralStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.